New legislation aimed at reforming federal science commercialization policies is gaining momentum in Congress, with House Small Business Committee Chairman Roger Williams introducing a companion bill to Senator Joni Ernst’s INNOVATE Act. The proposed legislation seeks to strengthen and reauthorize the Small Business Innovation Research (SBIR) program before its impending expiration at the fiscal year’s end.
The SBIR program, established in 1982, has played a crucial role in transforming scientific research into successful commercial ventures, with notable success stories including Qualcomm, ViaSat,
AeroVironment, and Anduril. The proposed reforms address several key challenges while building upon security improvements implemented in 2022.
A central feature of the legislation is the introduction of a $75 million lifetime cap on SBIR awards, designed to prevent companies from becoming perpetually dependent on the program. This measure responds to findings from the Government Accountability Office and other analysts who identified that a small number of companies were receiving disproportionate funding while demonstrating lower commercialization success rates.
The legislation also strengthens security measures following concerns about foreign influence. This comes after the Pentagon’s 2021 discovery of SBIR recipients transferring research results to Chinese entities. Despite previous security enhancements, the Senate Small Business Committee has identified ongoing issues with companies tied to foreign adversaries receiving awards, necessitating more robust due diligence processes.
To support emerging technologies, the INNOVATE Act introduces mechanisms to help companies bridge the “valley of death” – the challenging period between research development and product
commercialization. This includes a new one-time SBIR award focused on commercialization and, in the Department of Defense, Strategic Breakthrough Funding awards of up to $30 million for mass production initiatives.
The House version differs from the Senate bill in several aspects. It includes a waiver system allowing companies to exceed the $75 million cap for national security reasons, with oversight from agency directors. The House bill also extends the Strategic Breakthrough Funding program beyond the Pentagon to any agency with an annual SBIR budget exceeding $100 million, potentially benefiting organizations like the Department of Energy and National Institutes of Health.
While the House version’s commercialization requirements are less stringent than the Senate’s, it maintains transparency through mandated reporting of waiver recipients in annual congressional SBIR reports. Experts suggest that the Small Business Administration should also identify waived companies in its SBIR database to facilitate public monitoring of multiple award recipients.
The expanded eligibility for Strategic Breakthrough Funding in the House version could require adjustments to accommodate the specific needs of energy and health startups, as the current language primarily addresses defense-related activities.
The SBIR program continues to serve as a vital instrument for converting scientific research into commercial success. With its impending expiration, the proposed reforms present an opportunity to enhance the program’s effectiveness while addressing security concerns and supporting innovative small businesses. The convergence of House and Senate efforts signals progress toward ensuring the program’s continuation with improved safeguards and efficiency measures.